Klaus Orlinger

Klaus Orlinger

Company: Hookipa Biotech

Job title: Chief Scientific Officer


A Novel Arenaviral Immunotherapy for Targeting Multiple Mutated KRAS Epitopes 1:30 pm

Introduction to HOOKIPAs Platform for induction of tumor specific CD8+ T-cell responses Overview on key clinical data demonstrating induction of unprecedented tumor specific CD8+ responses in humans Overview and preclinical validation of HOOKIPA’s HB700 program targeting most frequent KRas mutations in pancreatic cancer, colorectal cancer and lung adenocarcinomaRead more

day: Day One Track C

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.